Introducing
Your new presentation assistant.
Refine, enhance, and tailor your content, source relevant images, and edit visuals quicker than ever before.
Trending searches
Atypical anti-psychotic Medication
Lumateperone (Caplyta) is a first-in-class selective and simultaneous modulator of serotonin, dopamine, and glutamate. Lumateperone received its first global approval in December 2019, here in the USA for the treatment of schizophrenia in adults (Correll et al., 2021).
.Extreme tiredness or fatigue
.Weight gain, nausea, dry mouth
.Dizziness, rash, hives
.Itching problems with coordination or increased falls unusual movements of your face or body that you cannot control
.Sore throat, fever, chills, or other signs of infection, fever; stiff muscles; sweating; confusion; sweating; or fast, pounding, or irregular heartbeat tightening of neck muscles or throat; or difficulty breathing or swallowing, seizures (Correll et al., 2021).
It works by changing the activity of certain natural substances in the brain which is adjusting serotonin and dopamine levels in the brain (Calabrese et al., 2021).
Lumateperone (Caplyta) received its first global approval in December 2019, here in the USA for the treatment of schizophrenia in adults.